Reports Q4 revenue $814,000, consensus $480,000. "We exited 2022 with a clear focus on our oncology pipeline and the initiation of the Phase 3 ACTION trial of ONC201 in patients with H3 K27M-mutant glioma. Patients with this deadly disease are in desperate need of therapeutic options and ONC201’s robust foundation of data underscores its potential as a highly differentiated asset. Following the monetization of TEMBEXA, we have a strong balance sheet to fully fund Chimerix into 2027, including through potential approval of ONC201. Recent independent analyses reported overall survival advantage in patients treated with ONC201, which has further reinforced our confidence in the ACTION trial and the commercial opportunity for ONC201," said Mike Sherman, Chief Executive Officer of Chimerix.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CMRX:
